RxDoctor Payments Data

Arsenio Favor, MD

Surgery · Demotte, INNPI 1104867068

Payments from drug & device makers

$8,952in general payments, 2019–2025

Across 415 payments — averaging $21.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • GSK$867
  • Sunovion Pharmaceuticals Inc.$582
  • Amgen$575
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$550
  • Amarin Pharma, Inc.$400
  • plus $4K from 35 others

What the payments were for

  • Food & beverage$8,952100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,952 in reported general payments places this provider in the 75th percentile of 524 surgery providers in Indiana.

See all surgery providers in Indiana

Medicare billing

Part B allowed, 2024
$83,109
Medicare patients
98
Services billed
8,208

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol182$151,418
Trelegy ElliptaFluticasone/Umeclidin/Vilanter97$84,036
EliquisApixaban124$59,375
OzempicSemaglutide34$51,885
KerendiaFinerenone56$30,596
JardianceEmpagliflozin45$30,438
TrintellixVortioxetine Hydrobromide61$29,593
Xigduo XrDapaglifloz Propaned/Metformin36$25,793
TrulicityDulaglutide22$21,970
XareltoRivaroxaban22$17,709
Breztri AerosphereBudesonide/Glycopyr/Formoterol25$16,797
LinzessLinaclotide11$15,210
NuedextaDextromethorphan Hbr/Quinidine16$12,445
Synjardy XrEmpagliflozin/Metformin Hcl21$11,970
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen427$10,387

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$1,692$168,215207 claims
GSKTrelegy Ellipta$867$84,03697 claims
PfizerEliquis$334$59,375124 claims
Boehringer IngelheimJardiance, Synjardy Xr, Synjardy, Tradjenta$276$55,098106 claims
Novo NordiskOzempic$63$51,88534 claims
BayerKerendia$321$30,59656 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$196$29,59361 claims
Lilly USA, LLCTrulicity$322$21,97022 claims
Johnson & JohnsonXarelto$386$17,70922 claims
AbbVieLinzess$21$15,21011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 524 surgery providers in Indiana.

Other surgery in Demotte

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →